Latest news with #AnnualScientificMeeting
Yahoo
5 days ago
- Health
- Yahoo
The Inner Circle acknowledges, Vijay S. Iyer, MD, Ph.D, FACC as a Pinnacle Lifetime Member
EAST AMHERST, N.Y., June 9, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, Vijay S. Iyer, MD, Ph.D, FACC is acknowledged as a Pinnacle Lifetime Member for his contributions to Complex Cardiac and Structural Interventions. Dr. Vijay S. Iyer, MD, Ph.D., FACC, is a distinguished interventional cardiologist specializing in complex cardiac and structural heart interventions. With a commitment to patient-centered care, Dr. Iyer focuses on advanced procedures such as mitral valve replacement, transcatheter aortic valve replacements (TAVR), and left atrial appendage occlusion. He is dedicated to educating his patients about their conditions and utilizing cutting-edge technology to enhance cardiac care in Western New York. Dr. Iyer earned his MBBS from Grant Medical College/University of Bombay, India, and pursued a Ph.D. in molecular pharmacology at Drexel University. His extensive training includes internal medicine residency at Lincoln Medical Center and the University of Buffalo, fellowships in molecular mechanisms of signaling and cardiovascular study at the University of Buffalo, and an interventional cardiology fellowship at the University of Minnesota. He is board certified in internal medicine, cardiology, and interventional cardiology. Affiliated with the American College of Cardiology, the Society of Coronary Artery Angiography and Intervention, and the American Heart Association, Dr. Iyer is also actively involved in fundraising and community health efforts. He serves as the Director of the Complex Valve Clinic at Buffalo General Medical Center and Gates Vascular Institute, where he oversees structural heart interventions and contributes to groundbreaking research. Dr. Iyer's career is marked by significant accomplishments, including his recognition with the Joel Gernsheimer Award in 2001 and the Best Research Poster Award at the MCP Hahnemann School of Medicine Annual Scientific Meeting in 1999. His published work includes white papers and training manuals/materials. Mentored by John Canty, MD, and Timothy Henry, MD, Dr. Iyer's future projections include advancing cardiology through research into new devices and therapies, as well as ongoing participation in multicenter clinical trials. His philosophy, "It's always a team effort," reflects his focus on patient education and collaborative decision-making. Contact: Katherine Green, 516-825-5634, editorialteam@ View original content to download multimedia: SOURCE The Inner Circle Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-06-2025
- General
- Yahoo
New Headache Medicine Research Impacting Treatment, Prevention and Quality of Life to be Presented at the American Headache Society® 67th Annual Scientific Meeting in Minneapolis, MN
MOUNT ROYAL, N.J., June 02, 2025--(BUSINESS WIRE)--The American Headache Society® (AHS) will host its 2025 Annual Scientific Meeting on June 19-22. Attendees can participate in-person or On Demand, gaining evidence-based information on diagnosing, managing, and treating headache disorders. "We are thrilled to advance the mission of the Society with this year's scientific conference," said Dr. Mark Burish, Co-Chair of the AHS Scientific Meeting Planning Committee. Co-Chair, Dr. Christina Szperka added, "This meeting has attracted an incredible array of speakers and faculty during an exciting time in headache medicine." The meeting includes lectures from pioneers and visionaries who have left an indelible mark on their respective fields. Among them is a pioneer in circadian biology, Joseph S. Takahashi PhD, who will provide the keynote. More than 300 abstracts will be presented in preclinical science, epidemiology, diagnosis, and treatment. This year's conference will include the first results of phase 3 trials of CGRP-targeted therapies in children and adolescents. New data will be unveiled that has the potential to have a significant impact on a broad range of patient populations, including: Traumatic Brain Injury Recovery Prediction with Brain MRI and CT Effectiveness of Treatments Used in New Daily Persistent Headache in Children and Adolescents Vaporized Cannabis Versus Placebo for the Acute Treatment of Migraine Understanding Headaches Associated with Enlarged Breast Tissue and the Impact of Surgery The meeting will also feature collections of talks at the intersection of headache and stroke, headache and sleep, headache and psychological trauma, and, for the first time in recent memory, a session devoted to the study of refractory headaches. The full meeting program is available on the AHS website here. AHS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. Attendees can earn up to 31.25 AMA PRA Category 1 Credits™ through live and recorded sessions. Media can obtain passes to gain access to all Annual Scientific Meeting content. Register for the meeting here. For more information about the American Headache Society and its events, programs, and membership, visit Live Meeting updates will be posted on all AHS outlets, @ahsheadache, and is easily searchable using #AHSAM. About the American Headache Society (AHS) The mission of the American Headache Society is to improve the care and lives of people living with headache disorders. The American Headache Society (AHS) is a professional society of health care providers dedicated to the study and treatment of headache and face pain. Educating physicians, health professionals and the public, and encouraging scientific research are the primary functions of our Society. For more information about the AHS, visit View source version on Contacts Tanya Kiniry, tkiniry@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
02-06-2025
- Health
- Business Wire
New Headache Medicine Research Impacting Treatment, Prevention and Quality of Life to be Presented at the American Headache Society ® 67 th Annual Scientific Meeting in Minneapolis, MN
MOUNT ROYAL, N.J.--(BUSINESS WIRE)--The American Headache Society ® (AHS) will host its 2025 Annual Scientific Meeting on June 19-22. Attendees can participate in-person or On Demand, gaining evidence-based information on diagnosing, managing, and treating headache disorders. 'This meeting has attracted an incredible array of speakers and faculty during an exciting time in headache medicine." "We are thrilled to advance the mission of the Society with this year's scientific conference,' said Dr. Mark Burish, Co-Chair of the AHS Scientific Meeting Planning Committee. Co-Chair, Dr. Christina Szperka added, 'This meeting has attracted an incredible array of speakers and faculty during an exciting time in headache medicine." The meeting includes lectures from pioneers and visionaries who have left an indelible mark on their respective fields. Among them is a pioneer in circadian biology, Joseph S. Takahashi PhD, who will provide the keynote. More than 300 abstracts will be presented in preclinical science, epidemiology, diagnosis, and treatment. This year's conference will include the first results of phase 3 trials of CGRP-targeted therapies in children and adolescents. New data will be unveiled that has the potential to have a significant impact on a broad range of patient populations, including: Traumatic Brain Injury Recovery Prediction with Brain MRI and CT Effectiveness of Treatments Used in New Daily Persistent Headache in Children and Adolescents Vaporized Cannabis Versus Placebo for the Acute Treatment of Migraine Understanding Headaches Associated with Enlarged Breast Tissue and the Impact of Surgery The meeting will also feature collections of talks at the intersection of headache and stroke, headache and sleep, headache and psychological trauma, and, for the first time in recent memory, a session devoted to the study of refractory headaches. The full meeting program is available on the AHS website here. AHS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. Attendees can earn up to 31.25 AMA PRA Category 1 Credits™ through live and recorded sessions. Media can obtain passes to gain access to all Annual Scientific Meeting content. Register for the meeting here. For more information about the American Headache Society and its events, programs, and membership, visit Live Meeting updates will be posted on all AHS outlets, @ahsheadache, and is easily searchable using #AHSAM. About the American Headache Society (AHS) The mission of the American Headache Society is to improve the care and lives of people living with headache disorders. The American Headache Society (AHS) is a professional society of health care providers dedicated to the study and treatment of headache and face pain. Educating physicians, health professionals and the public, and encouraging scientific research are the primary functions of our Society. For more information about the AHS, visit
Yahoo
18-02-2025
- Health
- Yahoo
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
Oral presentation on an efficacy study conducted in Japanese patients comparing anaphylaxis symptoms during oral food challenge with as the initial treatment compared to site historical data on intramuscular auto-injectors, antihistamines and inhalers; patients receiving had lower symptom scores within 10 minutes, supporting as a needle-free option for management of anaphylaxis was shown to be in the safe and efficacious range for children four years or older who weigh more than 15 kilograms Findings in Chinese studies confirms U.S. data and bracketed pharmacokinetic (PK) and pharmacodynamic (PD) profiles, demonstrate comparable efficacy and safety under various conditions including self-administration, allergic rhinitis, infectious rhinitis, in allergy challenges and with repeat dosing, compared with intermuscular injection SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that nine presentations will be featured at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting, February 28 to March 3, in San Diego, California. The oral presentation and posters will feature data from a wide range of studies, including pharmacokinetics and pharmacodynamics of intranasal epinephrine under normal and various conditions, physiological responses between adults and children who are administered epinephrine, and the pre-treatment journey of patients with allergic conditions. In addition to the presentations, ARS Pharma will participate in and host a variety of onsite activities during the meeting. 'We look forward to sharing additional findings from our comprehensive clinical research program with the broader allergy community at AAAAI and expect that the data will continue to build on the existing robust data on the efficacy and safety of intranasal epinephrine administration,' said Sarina Tanimoto, MD, PhD, Co-Founder and Chief Medical Officer of ARS Pharma the maker of (epinephrine nasal spray), the first and only FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.). 'As one of the leading companies actively conducting research in this critical space, we remain committed to advancing the scientific knowledge base of epinephrine so we can contribute to the allergy community.' The complete list of presentations and meeting activities is below. Abstracts can be viewed at Attendees are encouraged to visit the ARS Pharma booth (#1315), oral and poster presentations as well as the product theatre to learn more about . Oral Presentation – March 1, 2025 Time: 2:45 p.m. - 2:55 p.m. PST Title: Superior Efficacy of Epinephrine Nasal Spray for the Relief of Symptoms Following an Oral Food Challenge Speaker: Kyohei Takahashi, MD, MPH, PhD Room: Convention Center, Upper Level, Room 6B Poster ID: 571 Poster Presentations – March 1, 2025 Poster Presentation #1 Time: 9:45 a.m. - 10:45 a.m. PST Title: Pharmacokinetics and Pharmacodynamics of Single Dose of Epinephrine Nasal Spray and Manual Intramuscular Injections via HCP and Self-administration in Chinese Subjects Under Normal Conditions Authors: Yun Liu, MD, Shumin Wang, PhD, Miao Yu, MD, PhD, Pingya Hu, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD Poster ID: 297 Poster Presentation #2 Time: 9:45 a.m. - 10:45 a.m. PST Title: Persistence to Treatment in Patients with Allergic Conditions Requiring Epinephrine Auto-Injector Prescription (EAI Rx) Authors: Autumn Burnette, MD, Raffi Tachdjian, MD, Nicole M. Chase, MD, Sarina Tanimoto, MD, PhD, Ayman Kafal, PhD, MPH Poster ID: 302 Poster Presentation #3 Time: 9:45 a.m. - 10:45 a.m. PST Title: Pharmacokinetics of Epinephrine Nasal Spray under Various Conditions Authors: David M. Fleischer, MD, John Oppenheimer, MD, David Bernstein, MD, Thomas B. Casale, MD, Jonathan M. Spergel, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD Poster ID: 290 Poster Presentation #4 Time: 9:45 a.m. - 10:45 a.m. PST Title: Difference in Physiology Between Adults and Children in Response to Epinephrine Administration Authors: Matthew J. Greenhawt, MD, David M. Fleischer, MD, Thomas B. Casale, MD, Michael A. Kaliner, MD, Neetu Talreja, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD Poster ID: 289 Poster Presentation #5 Time: 9:45 a.m. - 10:45 a.m. PST Title: Understanding the Pre-Treatment Journey of Patients with Allergic Conditions: Insights from Patient Demographics and Diagnostic Pathways Authors: Raffi Tachdjian, MD, Autumn Burnette, MD, Nicole M. Chase, MD, Sarina Tanimoto, MD, PhD, Ayman Kafal, PhD, MPH Poster ID: 291 Poster Presentation #6 Time: 9:45 a.m. - 10:45 a.m. PST Title: Pharmacokinetics and Pharmacodynamics of Single Dose of Epinephrine Nasal Spray and Manual Intramuscular Injection in Chinese Subjects Under Allergic Rhinitis Conditions Authors: Jianting Wang, MD, PhD, Shumin Wang, PhD, Miao Yu, MD, PhD, Jiaowei Lu, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD Poster ID: 318 Poster Presentation #7 Time: 9:45 a.m. - 10:45 a.m. PST Title: Total Nasal Symptom Scores Remain Consistent in Response to Repeated Nasal Allergen Challenges Authors: Anne K. Ellis, MD, Michael A. Kaliner, MD, Carlos A. Camargo, Jr., MD, DrPH, John Oppenheimer, MD, David Bernstein, MD, Thomas B. Casale, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD Poster ID: 483 Poster Presentation #8 Time: 9:45 a.m. - 10:45 a.m. PST Title: Pharmacokinetics and Pharmacodynamics of Repeat Dose of Epinephrine Nasal Spray and Manual Intramuscular Injection in Chinese Subjects Under Normal Conditions Authors: Shumin Wang, PhD, Jianting Wang, MD, PhD, Miao Yu, MD, PhD, Jiaowei Lu, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD Poster ID: 317 Onsite Activities Joint Congress Opening Ceremony and Welcome Reception Date: February 27, 2025 Time: 4:15 p.m. - 5:45 p.m. PST Location: Convention Center - Ground Level Room 6A Non-CME Corporate Forum (Product Theatre) Date: February 27, 2025 Time: 6:30 p.m. - 8:30 p.m. PST Location: Marriott Marquis San Diego Marina - North Tower, Lobby Level Grand Ballroom Salon 4 Exhibit Booth Date: February 28-March 2, 2025 Location: #1315 About is an intranasal epinephrine product for patients with Type I allergic reactions due to insect stings or bites, foods, medicinal products, other allergens, as well as idiopathic or exercise induced anaphylaxis that could lead to life-threatening anaphylaxis. INDICATION AND IMPORTANT SAFETY INFORMATION FOR (epinephrine nasal spray) INDICATION2 mg is indicated for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater. IMPORTANT SAFETY INFORMATIONIt is recommended that patients are prescribed and have immediate access to two nasal sprays at all times. In the absence of clinical improvement or if symptoms worsen after initial treatment, administer a second dose of in the same nostril with a new nasal spray starting 5 minutes after the first dose. is for use in the nose only. Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required. Absorption of may be affected by underlying structural or anatomical nasal conditions. Administer with caution to patients who have heart disease; epinephrine may aggravate angina pectoris or produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics. The presence of a sulfite in should not deter use. may alter nasal mucosa for up to 2 weeks after administration and increase systemic absorption of nasal products, including . Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in patients with the following: hyperthyroidism, Parkinson's disease, diabetes, renal impairment. Epinephrine should be administered with caution in patients with these conditions, including elderly patients and pregnant women. Adverse reactions to may include throat irritation, intranasal paresthesia, headache, nasal discomfort, feeling jittery, paresthesia, fatigue, tremor, rhinorrhea, nasal pruritus, sneezing, abdominal pain, gingival pain, hypoesthesia oral, nasal congestion, dizziness, nausea, and vomiting. These are not all of the possible side effects of . To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or FDA at 1-800-FDA-1088 or For additional information on , please see Full Prescribing Information at About Type I Allergic Reactions Including Anaphylaxis Type I allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine auto-injectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 40 million people in the United States who experience Type I allergic reactions. Of this group approximately 20 million people have been diagnosed and treated for severe Type I allergic reactions that may lead to anaphylaxis, but (in 2023, for example) only 3.2 million filled their active epinephrine auto-injector prescription, and of those, only half consistently carry their prescribed auto-injector. Even if patients or caregivers carry an auto-injector, more than half either delay or do not administer the device when needed in an emergency. About ARS Pharmaceuticals, Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The company is commercializing 2 mg (trade name EUR in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, other allergens, as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit ARS Pharma Investor Contact: Justin ChakmaARS Pharmajustinc@ ARS Pharma Media Contact:Christy CurranSam Brown Inc. 615.414.8668christycurran@ in to access your portfolio
